Skip to content

Prevalence and Effect of Lifestyle Modification on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia

Prevalence and the Effect of Lifestyle Modification Project (LMP) on Clinical Outcomes and Cost-effectiveness Ratio for Sarcopenia in Chinese Adults and Elderly: a Multicenter Randomized Controlled Trail

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02873676
Enrollment
200
Registered
2016-08-19
Start date
2016-03-31
Completion date
2020-12-31
Last updated
2020-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sarcopenia

Keywords

prevalence; lifestyle modification; clinical outcomes

Brief summary

The purposes of this study were to investigate the prevalence and risk factors for sarcopenia in Chinese adults and elderly, and evaluate the effect of Lifestyle Modification Project (LMP) on Clinical Outcomes, Quality of Life and Cost-effectiveness Ratio.

Interventions

BEHAVIORALnutritional intervention

The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)

The training program involve warm-up exercise, muscle strength training and relaxing

BEHAVIORALlifestyle modification project

Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training

BEHAVIORALcontrol

The intervention involve dietary pattern modification and protein intake standardization

Sponsors

Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age\>=18 year The participants must have basic cognitive function and communication Must be able to provide a written informed consent

Exclusion criteria

* age\<18 year Concurrent severe cardiac disease, unstable diabetes mellitus,uncontrolled chronic disease,liver and renal failer, which may significantly interfere with study compliance. Participants received any drugs or supplements known to influence effcet size,such as protein powder, calcium, or vitamin D before the 3 months preceding the study. Participants with electronic or mental device

Design outcomes

Primary

MeasureTime frameDescription
relative skeletal muscle index3 monthsRSMI(Unit: kg/m2)is defined as muscle mass

Secondary

MeasureTime frameDescription
gait speed3 monthsGP(Unit: s)is defined as physical activity level
quality of life on EQ-5D scale3 monthsScores range from 0 \[worse\] to 1\[best\](Unit on a scale)
The rate of fracture3 monthsrate of participants with fracture due to fall(Unit: %)
Hand grip3 monthsHG(Unit: kg)is defined as muscle strength
the rate of infection complication3 monthsRate of participants with infection complication due to sarcopenia(Unit: %)
mortality rate3 monthsRate of participants mortality(Unit: %)
medical cost on cost-effectiveness ratio3 monthsthe lower cost,the higher effectiveness(Unit: %)
the change of physical function on frail index3 monthsScores range from 0 \[normal\] to 1\[unhealth\](Unit on a scale)

Countries

China

Contacts

Primary ContactKang Yu
yuk1997@sina.com+86 10 69155550

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 21, 2026